Divestiture • Life Science

Bain Capital Private Equity Acquires Mitsubishi Tanabe Pharma

On February 7, 2025, private equity firm Bain Capital Private Equity acquired life science company Mitsubishi Tanabe Pharma from Mitsubishi Chemical for 3.3B USD

Acquisition Context
  • This is Bain Capital Private Equity’s 13th transaction in the Life Science sector.
  • This is Bain Capital Private Equity’s 16th largest (disclosed) transaction.
  • This is Bain Capital Private Equity’s 15th transaction in Japan.

Explore All 789 Divestiture Life Science Deals - Search the Database Free


M&A Deal Summary

Date February 7, 2025
Target Mitsubishi Tanabe Pharma
Sector Life Science
Buyer(s) Bain Capital Private Equity
Sellers(s) Mitsubishi Chemical
Deal Type Divestiture
Deal Value 3.3B USD

Target Company

Mitsubishi Tanabe Pharma

Osaka, Japan
Mitsubishi Tanabe Pharma is a research-driven pharmaceutical company that specializes in the research, development, and marketing of globally competitive pharmaceutical products focused on the field of autoimmune disease, diabetes and kidney disease, and CNS disease. Mitsubishi Tanabe Pharma was founded in 1933 and is based in Osaka, Japan.
Explore More Deals

Browse All 215,156 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Bain Capital Private Equity

Boston, Massachusetts, United States

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1984
PE ASSETS 44.2B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

Bain Capital Private Equity (BCPE), is the private equity investment arm of alternative asset management firm, Bain Capital. BCPE targets leveraged buyout and growth capital transactions in a wide variety of industries including information technology, communications, media, healthcare, industrial/manufacturing, retail/consumer, and financial services. Bain Capital is based in Boston with additional offices in New York, London, Mumbai, Hong Kong, Shanghai, Tokyo, and Munich.


Deal Context for Buyer #
Overall 246 of 253
Sector: Life Science 13 of 13
Type: Divestiture 38 of 38
Country: Japan 15 of 15
Year: 2025 4 of 11
Size (of disclosed) 16 of 75
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2025-02-05 Milacron

Cincinnati, Ohio, United States

Milacron provides plastics processing equipment, technologies, and services. It offers hot runner systems, temperature controllers, and auxiliary equipment; and mold bases, mold components, cold runner systems, and control systems for the plastics industry. Milacron was founded in 2000 and is based in Cincinnati, Ohio.

Buy $287M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2025-02-14 Apleona

Neu-Isenburg, Germany

Apleona is a real estate services provider, that operates, manage, expand and equip real estate in all asset classes, operate and maintain plant and assist customers in a whole host of industries with production and secondary processes. The Group's range of services extends from integrated facility management, building technology, and interior fittings to real-estate management with all commercial services, letting and leasing of real estate. All services are provided on a modular basis or in an integrated package. Apleona was founded in 2016 and is based in Neu-Isenburg, Germany.

Buy -

Seller Profile 1

SELLER

Mitsubishi Chemical

Tokyo, Japan

Category Company
Founded 2005
Sector Chemicals
Employees63,258
Revenue 4.41T JPY (2025)
DESCRIPTION

Mitsubishi Chemical provides chemistry-based technology platforms for the development of a wide range of technologies and products in the fields of performance products, healthcare, and industrial materials. Mitsubishi Chemical was founded in 2005 and is based in Tokyo, Japan.


Deal Context for Seller #
Overall 2 of 2
Sector: Life Science 1 of 1
Type: Divestiture 2 of 2
Country: Japan 2 of 2
Year: 2025 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-11-18 Mitsubishi Tanabe Pharma

Osaka, Japan

Mitsubishi Tanabe Pharma is a research-driven pharmaceutical company that specializes in the research, development, and marketing of globally competitive pharmaceutical products focused on the field of autoimmune disease, diabetes and kidney disease, and CNS disease. Mitsubishi Tanabe Pharma was founded in 1933 and is based in Osaka, Japan.

Buy -

Explore Related M&A Activity